ALT (Altimmune) Shiller PE Ratio: (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALT Altimmune Inc ALT
32 GF Score
Price $3.29
! 2 Warning Signs
View Full Analysis

What is Altimmune Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Altimmune  (NAS:ALT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Altimmune Shiller PE Ratio Related Terms


Altimmune Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Altimmune's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altimmune Shiller PE Ratio Chart

Altimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Altimmune Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ALT vs ARVN, AUTL, EIKN: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Altimmune's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altimmune Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Altimmune's Shiller PE Ratio falls into.


ALT
32GF Score
Altimmune Inc ALT
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altimmune Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Altimmune's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Altimmune's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.12/333.9520*333.9520
=-0.120

Current CPI (Jun. 2026) = 333.9520.

Altimmune Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -21.300 241.428 -29.463
201612 -13.800 241.432 -19.088
201703 -20.400 243.801 -27.943
201706 -7.800 244.955 -10.634
201709 -61.570 246.819 -83.306
201712 -16.150 246.524 -21.877
201803 -7.490 249.554 -10.023
201806 -10.290 251.989 -13.637
201809 -1.730 252.439 -2.289
201812 -2.786 251.233 -3.703
201903 -0.270 254.202 -0.355
201906 -0.260 256.143 -0.339
201909 -0.740 256.759 -0.962
201912 -0.250 256.974 -0.325
202003 -0.260 258.115 -0.336
202006 -0.940 257.797 -1.218
202009 -0.540 260.280 -0.693
202012 -0.170 260.474 -0.218
202103 -0.380 264.877 -0.479
202106 -0.600 271.696 -0.737
202109 -0.810 274.310 -0.986
202112 -0.570 278.802 -0.683
202203 -0.440 287.504 -0.511
202206 -0.420 296.311 -0.473
202209 -0.480 296.808 -0.540
202212 -0.430 296.797 -0.484
202303 -0.400 301.836 -0.443
202306 -0.320 305.109 -0.350
202309 -0.390 307.789 -0.423
202312 -0.560 306.746 -0.610
202403 -0.340 312.332 -0.364
202406 -0.350 314.175 -0.372
202409 -0.320 315.301 -0.339
202412 -0.330 315.605 -0.349
202503 -0.260 319.799 -0.272
202506 -0.270 322.561 -0.280
202509 -0.210 324.800 -0.216
202512 -0.270 324.054 -0.278
202603 -0.180 330.213 -0.182
202606 -0.120 333.952 -0.120

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Altimmune Business Description

Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
32GF Score

Get the complete analysis for ALT

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price